In the pursuit of market outperformance, investors navigate the landscape of stock selection. The right picks can play a pivotal role in enhancing your wealth.
Fulcrum Therapeutics Inc (NASDAQ: FULC) closed the day trading at $8.9 up 1.60% from the previous closing price of $8.76. In other words, the price has increased by $1.60 from its previous closing price. On the day, 1.68 million shares were traded. FULC stock price reached its highest trading level at $9.67 during the session, while it also had its lowest trading level at $8.63.
Ratios:
For a better understanding of FULC, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 17.70 and its Current Ratio is at 17.70. In the meantime, Its Debt-to-Equity ratio is 0.04 whereas as Long-Term Debt/Eq ratio is at 0.02.
On July 29, 2025, H.C. Wainwright Upgraded its rating to Buy which previously was Neutral and also upped its target price recommendation from $4 to $12.
Leerink Partners Upgraded its Market Perform to Outperform on May 23, 2025, while the target price for the stock was maintained at $12.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Nov 19 ’25 when Gould Robert J sold 15,000 shares for $11.03 per share. The transaction valued at 165,495 led to the insider holds 484,864 shares of the business.
ROBERT J GOULD bought 45,000 shares of FULC for $437,850 on Nov 19 ’25. On May 08 ’25, another insider, Tourangeau Greg, who serves as the Principal Accounting Officer of the company, sold 498 shares for $5.06 each. As a result, the insider received 2,520 and left with 14,062 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, FULC now has a Market Capitalization of 481654080 and an Enterprise Value of 288020096.
Stock Price History:
The Beta on a monthly basis for FULC is 3.22, which has changed by 1.2194514 over the last 52 weeks, in comparison to a change of 0.13506866 over the same period for the S&P500. Over the past 52 weeks, FULC has reached a high of $12.19, while it has fallen to a 52-week low of $2.32. The 50-Day Moving Average of the stock is -4.52%, while the 200-Day Moving Average is calculated to be 34.82%.
Shares Statistics:
Over the past 3-months, FULC traded about 649.19K shares per day on average, while over the past 10 days, FULC traded about 721680 shares per day. A total of 54.11M shares are outstanding, with a floating share count of 48.00M. Insiders hold about 11.30% of the company’s shares, while institutions hold 89.92% stake in the company. Shares short for FULC as of 1763078400 were 3564671 with a Short Ratio of 5.49, compared to 1760486400 on 3550355. Therefore, it implies a Short% of Shares Outstanding of 3564671 and a Short% of Float of 9.51.
Earnings Estimates
Currently, 10.0 analysts are dedicated to thoroughly evaluating and rating the performance of Fulcrum Therapeutics Inc (FULC) in the stock market.The consensus estimate for the next quarter is -$0.3, with high estimates of -$0.22 and low estimates of -$0.34.
Analysts are recommending an EPS of between -$1.14 and -$1.24 for the fiscal current year, implying an average EPS of -$1.19. EPS for the following year is -$1.23, with 10.0 analysts recommending between -$0.86 and -$1.54.
